Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management

Jafar Kafaie, MD, PhD


June 24, 2021

Although evidence regarding long-term management of CIDP is limited, patients benefiting from long-term IVIg treatment who become refractory to IVIg become responsive to the therapy again after a short course of plasma exchange.

Patients with very mild symptoms that do not significantly interfere with activities of daily living may not require treatment. However, therapy with corticosteroids or IVIg should be offered to patients with moderate or severe disability.

Immunosuppression may be required particularly in cases of atypical disease or long-term course, or when the response to corticosteroids, IVIg, or plasma exchange is inadequate.

Approximately two thirds of patients will need IVIg, and 15%-30% of patients require only a single course of IVIg.

Learn more about medication in CIDP treatment.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.